Workflow
Vertex(VRTX)
icon
Search documents
Vertex(VRTX) - 2023 Q1 - Earnings Call Presentation
2023-05-01 20:38
FIRST QUARTER 2023 FINANCIAL RESULTS ©2023 Vertex Pharmaceuticals Incorporated VERTEX MAY 1, 2023 AGENDA Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Operating Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2023 Vertex Pharmaceuticals Incorporated 2 SAFE HARBOR STAT ...
Vertex(VRTX) - 2023 Q1 - Quarterly Report
2023-05-01 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Pharmaceuticals Incorpor ...
Vertex Pharmaceuticals Incorporated (VRTX) 43rd Annual Cowen Healthcare Conference Transcript
2023-03-08 00:51
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual Cowen Healthcare Conference March 7, 2023 2:50 PM ET Company Participants Reshma Kewalramani – President and Chief Executive Officer Charlie Wagner – Chief Financial Officer Conference Call Participants Phil Nadeau – Cowen Phil Nadeau [Call Starts Abruptly] Annual Healthcare Conference. IÂ'm Phil Nadeau, one of CowenÂ's biotech analysts, and itÂ's my pleasure to do a fireside chat with one of the bellwethers of the industry, Vertex. Happy to have ...
Vertex(VRTX) - 2022 Q4 - Annual Report
2023-02-09 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts 04-3039129 (State or other jurisd ...
Vertex(VRTX) - 2022 Q4 - Earnings Call Transcript
2023-02-08 02:10
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2022 Earnings Conference Call February 7, 2023 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Reshma Kewalramani - Chief Executive Officer and President Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Geoff Meacham - Bank of America Phil Nadeau - Cowen Liisa Bayko - Evercore ISI David Risinger - SVB Robyn Karnauskas - Tru ...
Vertex(VRTX) - 2022 Q4 - Earnings Call Presentation
2023-02-07 23:09
FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ©2023 Vertex Pharmaceuticals Incorporated VERTEX FEBRUARY 7, 2023 AGENDA Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Operating Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2023 Vertex Pharmaceuticals Incorporate ...
41st Annual J.P. Morgan Healthcare Conference
2023-01-09 18:06
VERTEX THE SCIENCE of POSSIBILITY J.P. MORGAN HEALTHCARE CONFERENCE RESHMA KEWALRAMANI, M.D. CEO AND PRESIDENT JANUARY 2023 ©2023 Vertex Pharmaceuticals Incorporated global.vrtx.com | --- | --- | --- | --- | --- | |--------------------------------------------|-------|----------|-------|-------| | | | | | | | SAFE HARBOR STATEMENT & NONGAAP FINANCIAL | | | | | | | | MEASURES | | | | | | | | | | | | | | | | ©2023 Vertex Pharmaceuticals Incorporated | | | | | This presentation contains forward-looking statemen ...
Vertex Pharmaceuticals Incorporated (VRTX) 41st Annual J.P. Morgan Healthcare Conference - (Transcript)
2023-01-09 18:04
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 41st Annual J.P. Morgan Healthcare Conference Call January 9, 2023 11:15 AM ET Company Participants Reshma Kewalramani - Chief Executive Officer and President Charlie Wagner - Chief Financial Officer Stuart Arbuckle - Chief Operating Officer David Altshuler - Executive Vice President, Global Research, and Chief Scientific Officer Conference Call Participants Jessica Fye - J.P. Morgan Jessica Fye Great. Good morning, everyone. Welcome. I'm Jessica Fye. I'm a ...